论文部分内容阅读
目的探讨灯盏生脉治疗2型糖尿病早期肾病的临床疗效。方法将90例2型糖尿病早期肾病患者随机分为2组,每组45例。A组为治疗组,采用灯盏生脉+依那普利治疗,B组为对照组,单用依那普利治疗。观察尿微量清蛋白排泄率(UALB)、血糖、血脂,比较2组患者的疗效。结果 2组患者治疗后UALB较治疗前均降低,差异均有统计学意义(P<0.01)。2组患者治疗后疗效比较,差异有统计学意义(P<0.05),A组优于B组。2组治疗前血清总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、差异均无统计学意义(P>0.05);但2组治疗后上述指标比较,差异有统计学意义(P<0.05),其中A优于B组。结论灯盏生脉与依那普利均能降低2型糖尿病早期肾病患者的UALB,但灯盏生脉联合依那普治疗效果优于单用依那普利,且灯盏生脉有改善血脂的作用。
Objective To investigate the clinical efficacy of Dengzhan Shengmai in the treatment of type 2 diabetic nephropathy. Methods Ninety patients with type 2 diabetic nephropathy were randomly divided into two groups (45 in each group). Group A was treated with Dengzhan Shengmai + Enalapril, Group B was control group, and enalapril alone. The urinary albumin excretion rate (UALB), blood glucose and lipids were observed. The curative effect was compared between the two groups. Results The UALB of the two groups after treatment was lower than that before treatment, the differences were statistically significant (P <0.01). The curative effect of two groups after treatment was statistically significant (P <0.05), A group was better than B group. There were no significant differences in serum total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) ), But there was a significant difference between the two groups after treatment (P <0.05), and A was superior to B group. Conclusion Both Denglian Shengmai and enalapril can reduce UALB in type 2 diabetic patients with early nephropathy, but Denglian Shengmai combined with enalapril is superior to enalapril alone, and Dengzhan Shengmai can improve blood lipid.